Flagship Cancer Research UK precision medicine trial

The lung cancer study which is led by the University of Birmingham’s Cancer Research UK Clinical Trials Unit, and has been published in Nature, highlights the importance of the new approaches needed when treating genomically complicated cancers.

The National Lung Matrix Trial (NLMT) is the world’s largest precision medicine clinical trial for non-small-cell lung cancer (NSCLC) patients, it is funded by Cancer Research UK (CRUK) and supported by the charity’s Stratified Medicine Programme Phase 2 (SMP2) screening platform.

The trial matches different treatment options to different groups of patients and since opening to recruitment in 2015, 288 patients have been recruited to the 19 different treatment cohorts in the trial.

You can read more about the trial here

12 views0 comments
  • LinkedIn
  • Facebook
  • Twitter
  • YouTube

This project has received funding from the European Union’s Horizon 

2020 research and innovation programme under grant agreement No 825046

The project is co-ordinated by Department Economy, Science and Innovation (EWI) of the Flemish Government.

Department Economy, Science and Innovation - Koning Albert II-laan 35 1030 Brussels, Belgium